Biognosys announces Nature Communications publication in collaboration with ETH Zurich, Bayer, and BASF
1.9.2020 09:00:00 EEST | Business Wire | Press release
Biognosys is pleased to announce the publication of new research findings in Nature Communications on the utility of its LiP technology and workflow for drug target identification. The publication, entitled “A Machine-Learning-Based Chemoproteomic Approach to Identify Drug Targets and Binding Sites in Complex Proteomes”, is co-authored by collaborators from ETH Zurich, Biognosys, Bayer and BASF.
In this publication, we present a novel chemoproteomic workflow combining LiP and machine learning-based data analysis. This next-generation proteomics approach enables the identification of small molecule drug targets in complex proteomes and the analysis of their binding properties across species and drug target classes.
Oliver Rinner, Chief Executive Officer of Biognosys, comments: “Understanding a compound’s mechanism of action remains a major challenge in drug development. This publication is a testimony to our commitment to support our pharma and biotech partners with unique applications for more efficient drug discovery.”
Lukas Reiter, Chief Technology Officer, states: “Biognosys’ quantitative proteomics technology based on data independent acquisition (DIA) is a perfect fit for the LiP technology. This combined workflow enabled us to develop a target deconvolution approach for human cell lines.”
Prof. Dr. Paola Picotti, Associate Professor in Molecular Systems Biology and head of the Picotti group at ETH Zurich, and Scientific Advisor for Biognosys, says: “With the LiP approach, we can now also identify compound-binding in very complex mammalian cell systems with high confidence. In addition, we get information on binding affinity, which helps us to prioritize targets for follow-up studies.”
Thomas Knobloch, Laboratory Manager at Bayer CropScience, adds: “The LiP technology is a very valuable tool to identify target and off-target of novel compounds whatever the organism and to support the process of target deconvolution in early phase research.”
Earlier this year, Biognosys published research findings demonstrating the utility of LiP-based proteomics for drug discovery at the US Human Proteome (HUPO) Conference and the American Association for Cancer Research (AACR) Annual Meeting.
About Limited Proteolysis (LiP)
The Limited Proteolysis technology coupled to next-generation quantitative mass spectrometry is a novel approach that enables the unbiased and proteome-wide profiling of protein changes resulting from a variety of stimuli such as heat shock, protein-protein interactions, compound binding, and posttranslational modifications.
Invented by the group of Prof. Paola Picotti at ETH Zurich, this patented technology is exclusively licensed to and co-developed by Biognosys to support pharma and biotech partners with contract research services for drug discovery and development. Biognosys already offers a LiP-technology based target deconvolution application and is developing additional, machine-learning-based applications for target validation.
For more information, click here.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by developing the most advanced proteomics tools and making them available for pharmaceutical and biotech research and development. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with an in-depth view of protein expression and regulation in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at www.biognosys.com
Reference
Piazza I et al. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes. Nature Communications (2020)11:4200.
DOI: 10.1038/s41467-020-18071-x
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005028/en/
Contact information
Media Contact:
Oliver Rinner, PhD
Chief Executive Officer
Phone +41 (0) 44 738 20 40
oliver.rinner@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Named to the CNBC World's Top Fintech Companies 2026 List23.7.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, has been named to CNBC's World's Top Fintech Companies 2026 list, in the Payments category. The list, now in its fourth edition, is produced by CNBC in partnership with Statista Inc., the global statistics and industry ranking firm. It was announced on July 22, 2026, and is available on CNBC's website. This is Riskified's second time making the list. The company previously earned this recognition in 2024, reinforcing its position in the ecommerce fraud and risk intelligence sector and underscoring its ongoing success in empowering businesses to grow revenue and profitability by mitigating risk through its AI-powered platform. CNBC and Statista's ranking covers the top 500 companies across eight fintech segments — Payments, Neobanking, Alternative Financing, Wealth Technology, Digital Assets, Enterprise Fintech, Insurtech, and Regtech. Companies are scored using an aggregated model that weighs ov
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 14:00:00 EEST | Press release
Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, investigators and advocacy groups who have made this milestone possible. As we advance the GM1/GM2 study toward data readout and regulatory submission, we continue to enroll in our Phase 3 NPC study and remain focused on our goal of addressing the significant unmet medical needs faced by these rare disease communities." Professor Roberto Giugliani, Princi
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds23.7.2026 14:00:00 EEST | Press release
Francisco Partners (“FP”), a leading global investment firm that specializes in partnering with technology companies, today announced the closing of $21 billion in capital commitments across its Francisco Partners VIII, L.P. flagship fund and Francisco Partners Agility IV, L.P., its middle-market fund. FP exceeded its initial targets of $14.0 billion and $3.5 billion, respectively. This milestone builds on Francisco Partners' longstanding track record of performance, underscored by its distinction as the only firm to rank among the top three performers in each of the past six HEC-Dow Jones Large Buyout Performance Rankings.* “In our business, long-term success is created through a series of relationships built on years of trust and collaboration," said Dipanjan (“DJ”) Deb, Co-Founder and CEO of Francisco Partners. "We want to thank our investors for their support, our management teams for their dedication and performance, our friends and partners throughout the technology ecosystem, ou
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 11:21:00 EEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 10:33:00 EEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom